Population-Based Fecal Testing May Reduce Colorectal Cancer Mortality

Share this content:
Population-based fecal immunochemical testing screening in adults aged 50 to 69 years can reduce colorectal cancer mortality.
Population-based fecal immunochemical testing screening in adults aged 50 to 69 years can reduce colorectal cancer mortality.

Population-based fecal immunochemical testing (FIT) screening in adults aged 50 to 69 years can reduce colorectal cancer (CRC) mortality, according to a study published in Cancer.

Han-Mo Chiu, Ph.D., from National Taiwan University, and colleagues conducted a prospective study of the follow-up of about five million Taiwanese from 2004 to 2009.

CRC mortality was compared for a screened group and an unscreened group in a population-based CRC screening service targeting 50- to 69-year-olds. Overall, 21.4 percent of the 5,417,699 subjects aged 50 to 69 years in the population participated in the biennial screening program by 2009.

The researchers found that, with a maximum follow-up of six years, the actual effectiveness of FIT in reducing CRC mortality was 62 percent (relative rate for screened versus unscreened group, 0.38).

RELATED: Regorafenib Improves Survival in Treatment-Refractory Colorectal Cancer

After adjustment for self-selection bias, the 21.4 percent coverage of the population receiving FIT correlated with a significant 10 percent reduction in CRC mortality (relative rate, 0.9).

"Although such findings are informative for health decision makers, continued follow-up of this large cohort will be required to estimate the long-term impact of FIT screening if the covered population is expanded," the authors write.

Reference

  1. Chiu, Han-Mo, PhD, et al. "Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program." Cancer. DOI: 10.1002/cncr.29462. [epub ahead of print]. May 20, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters